1. Hauptnavigation
  2. Navigation des Hauptbereiches
  3. Inhalt der Seite

Ausgewählte Publikationen

Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Försti A, Vijayakrishnan J, Migliorini G, Dobbins SE, Holroyd A, Hose D, Walker BA, Davies FE, Gregory WA, Jackson GH, Irving JA, Pratt G, Fegan C, Fenton JA, Neben K, Hoffmann P, Nöthen MM, Mühleisen TW, Eisele L, Ross FM, Straka C, Einsele H, Langer C, Dörner E, Allan JM, Jauch A, Morgan GJ, Hemminki K, Houlston RS, Goldschmidt H. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk.NatGenet 2013 [Epub ahead of print]

Dutruel C, Bergmann F, Rooman I, Zucknick M, Weichenhan D, Geiselhart L, Kaffenberger T, Rachakonda PS, Bauer A,Giese N, Hong C, Xie H, Costello JF, Hoheisel J, Kumar R,Rehli M, Schirmacher P, Werner J, Plass C, Popanda O, Schmezer P. Early epigenetic downregulation of WNK2 kinase during pancreatic ductal adenocarcinoma development. Oncogene 2013

Hemminki K. Familial risks in understanding type 1 diabetes genetics. Nat Rev Genet 2012;13:146. Hemminki K, Li X, Försti A, Sundquist J, Sundquist K. Non-Hodgkin lymphoma in familial amyloid polyneuropathy patients in Sweden.Blood 2013;122(3):458-9.

Horn S, Figl A, Rachakonda SP, Fischer C, Sucker A, Gast A, Kadel S, Moll, I Nagore E, Hemminki K, Schadendorf D, Kumar R. TERT Promoter Mutations in Familial and Sporadic Melanoma. Science 2013;339(6122):959-61.

Kharazmi E, Pukkala E, Sundquist K, Hemminki K. Familial risk of small intestinal carcinoid and adenocarcinoma.Clin Gastroenterol Hepatol 2013;11(8):944-9.

Lenci RE, Bevier M, Brandt A, Bermejo JL, Sucker A, Moll I, Planelles D, Requena C, Nagore E, Hemminki K, Schadendorf D, Kumar R. Influence of genetic variants in type I interferon genes on melanoma survival and therapy. PLoS One 2012;7:e50692

Leonardi G, Vahter M, Clemens F, Goessler W, Gurzau E, Hemminki K, Hough R, Koppova K, Kumar R, Rudnai P, Surdu S, Fletcher T. Arsenic and Basal Cell Carcinoma in Riihimäki M, Thomsen H, Hemminki A, Sundquist K, Hemminki K. Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer. BMC Cancer 2013;13:36.

Rachakonda PS, Bauer AS, Xie H, Campa D, Rizzato C, Canzian F, Beghelli S, Greenhalf W, Costello E, Schanne M, Heller A, Scarpa A, Neoptolemos JP, Werner J, Büchler M, Hoheisel JD, Hemminki K, Giese N, Kumar R. Somatic mutations in exocrine pancreatic tumors: association with patient survival.PLoS One 2013;8(4):e60870.

Weinhold N, Johnson DC, Chubb D, Chen B, Försti A, Hosking FJ, Broderick P, Ma YP, Dobbins SE, Hose D, Walker BA, Davies FE, Kaiser MF, Li NL, Gregory WA, Jackson GH, Witzens-Harig M, Neben K, Hoffmann P, Nöthen MM, Mühleisen TW, Eisele L, Ross FM, Jauch A, Goldschmidt H, Houlston RS, Morgan GJ, Hemminki K. The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet 2013 [Epub ahead of print]



Letzte Aktualisierung: 25.09.2013 Seitenanfang